Nothing Special   »   [go: up one dir, main page]

Hypertension in Pregnancy - Malang 23-9-201

Download as pdf or txt
Download as pdf or txt
You are on page 1of 34

Hypertension

in Pregnancy

Syakib Bakri
Makassar
Maternal mortality ratios for 2000 by medical cause
and world region

Ronsmans C, Graham WJ. Lancet 2006; 368:1189-1200.


Population-Level, Cause-Specific Proportionate Pregnancy-
Related Mortality

Creanga AA et al. Obstet Gynecol. 2017; 30:1-8


Circulatory Changes During Normal Pregnancy

Ouzounian J, Elkayam U. Cardiol Clin. 2012;30:317-329


Changes in Regional Blood Flow During Normal Pregnancy

Ouzounian J, Elkayam U. Cardiol Clin. 2012; 30:317-329


Classifica8on of Hypertension in Pregnancy

•  Chronic (pre-exis/ng) hypertension


•  Gestasional hypertension
•  Preeclampsia-Eclampsia
•  Super imposed preeclampsia in chronic
hypertension
Diagnosis of Hypertension in Pregnancy
•  Hypertension : Systolic Blood Pressure (SBP) ≥140
mmHg and/or Diastolic Blood Pressure (DBP) ≥90 mmHg
•  NICE Guidelines :
Mild: 140-149/90-99 mmHg
Moderate: 150-159/100-109 mmHg
Severe: ≥ 160/110 mmHg
•  American College of Obstetrician and Gynaecologists :
Mild: 140-150/90-109 mmHg
Severe : ≥ 160/110 mmHg
BP measurement
•  BP measurement in pregnancy should use non-
pregnancy standardized technique.
•  Non-severely elevated BP should be confirmed by
repeat measurement, at least 15 min apart at
that visit.
•  Up to 70% of women with non-severely elevated
BP an office measurement have a normal BP on
subsequent measurements on the same visit, or
by ambulatory blood pressure monitor or home
blood pressure measurement.
Chronic (pre-existing) Hypertension

•  Blood pressure ≥140/90 mmHg present before pregnancy,


before the 20th week of gestation, or persisting beyond the
6wk (12wk) postpartum.

•  1%-5% of pregnancies

•  90% essential or primary hypertension, 10% may have


underlying renal or endocrine disease

Vest AR, ChoL S. Cardiol. Clin. 2012;30:407-423


High risk chronic hypertension in pregnancy

•  Secondary hypertension
•  Target organ damage
•  Maternal age ≥40 years
•  Microvascular disease
•  Previous loss
•  BP ≥180/110 mmHg
Univariate logistic regression analysis demonstrating the
association of chronic hypertension with pregnancy
complications
Gestational Hypertension

•  Hypertension that (1) develops beyond 20 wk of gestation;


(2) can be with or without proteinuria, but is not associated
with other features of preeclampsia; and (3) usually
resolves within 6wk (12wk) postpartum

•  6%-7% of pregnancies

Vest AR, ChoL S. Cardiol. Clin. 2012;30:407-423


Preeclampsia/Eclampsia

•  Hypertension presenting beyond 20wk of gestation with


>300 mg protein in a 24-h urine collection or >30 mg/mmol
in a spot urine sample. Eclampsia is the occurrence of
seizures in a pregnant woman with preeclampsia

•  5%-7% of pregnancies

Vest AR, ChoL S. Cardiol. Clin. 2012;30:407-423


Diagnostic Criteria for Preeclampsia (1)

Robert JM et al. Am Coll Obstetric Gynecol. 2013:4.


Diagnostic Criteria for Preeclampsia (2)

Robert JM et al. Am. Coll. Obstet. Gynecol. 2013:4.


Superimposed preeclampsia in chronic hypertension

•  The onset of features diagnostic of preeclampsia in a


woman with chronic hypertension beyond 20 wk of
gestation

•  20%-25% of chronic hypertension pregnancies

Vest AR, ChoL S. Cardiol. Clin. 2012;30:407-423


Outcomes of pregnancy in women
chronic hypertension
Outcame No pre-eclampsia With superimposed pre-
eclampsia
Preterm birth 15% 51%
<37/40
Preterm birth 7% 23%
<34/40
Caesarean sec/on 44% 70%
SGA 21% 48%
BW <2.5kg 13% 44%

SGA : <10th cen/le using customised growth charts, BW, birthweight

Chappell LC et al,Hypertension 2008;51:1002-1009


Risk Factor for Preeclampsia

•  Advance maternal age


•  Nulliparity
•  Previous preeclampsia
•  Family history of preeclampsia
•  Multifetal gestation
•  Preexisting medical condition
ü Diabetes
ü Chronic hypertension
ü Renal disease
ü Systemic lupus erythematosus
ü Antiphospholipid antibody syndrome
•  Baseline proteinuria
•  Prolonged time between pregnancies
•  Increased body mass index
•  Baseline hypertension

Naderi S et al. Hypertensive disorder of pregnancy. Curr Atheroscler. Rep. 2017;19:15-21.


Diagnostic Criteria of Severe Preeclampsia

Townsend R, et al . Integr Blood Press Contr. 2016;9:79-94


Maternal and Fetal Complications in Severe Preeclampsia

Maternal Complications
Abruptio placentae (1% - 4%)
Disseminated coagulopathy / HELLP syndrome (10% - 20%)
Pulmonary edeme / aspiration (2% - 5%)
Acute renal failure (1% - 5%)
Eclampsia (<1%)
Liver failure of hemorrhage (<1%)
Stroke (rare)
Death (rare)
Long-term cardiovascular morbidity

Neonatal Complications
Preterm delivery (15% - 67%)
Fetal growth restriction (10% - 25%)
Hypoxia-neurologic injury (<1%)
Perinatal death (1% - 2%)
Long-term cardiovascular morbidity associated with low birth weight (fetal origin of adult
disease)
Pathogenesis of preeclampsia: two-stage
model

AT1-AA, autoan/bodies to angiotensin receptor 1; COMT, catechol-O-methyltransferase; HTN, hypertension; LFT, liver
func/on test; PlGF1, placental growth factor 1; PRES, posterior reversible encephalopathy syndrome; sEng, soluble endoglin;
sFlt-1, soluble fms–like tyrosine kinase 1; sVEGFR1, soluble vascular endothelial growth factor receptor 1; VEGF, vascular
endothelial growth factor

Clin J Am Soc Nephrol 11: 1102–1113,2016


The Two Stages of Preeclampsia

Stage 1
Poor
First half of No symptoms
placenta/on
pregnancy

Stage 2 Placental oxida/ve


Overt
Second half of stress and
pre-eclampsia
pregnancy inflamma/on

sFlt-1 and other


syncy/othropoblast derived
factors

Maternal systemic
inflammatory stress

Clinical sign of
pre-eclampsia
Aims of an8hypertensive treatment
•  Prevent and treat severe hypertension
•  Prolong pregnancy for as long as safety
possible
•  Maximizing the gesta/onal age of the
newborn
•  Minimize fetal exposure to medica/on that
may have adverse effects

Some facts related to ini/a/on an/-hypertensive
drugs in pregnant women with mild hypertension:


•  Lack of evidence that treatment of mild hypertension in pregnancy
leads to improved maternal outcomes
•  Assump/on that mild hypertension of 4–5 months dura/on does
not adversely affect immediate and long-term cardiovascular
disease (CVD)
•  Concern that decreased maternal BP may compromise
uteroplacental and fetal circula/on, thus, resul/ng in small-for-
gesta/onal–age (SGA) infant
•  Poten/al increase in risk for fetal adverse effects due to exposure
to poten/ally harmful medica/ons in utero.
Summary of society guidelines regarding blood
pressure treatment thresholds and targets

Abbrevia/ons: NHBPEP, the Na/onal High Blood Pressure Educa/on Program; ACOG, American College of
Obstetricians and Gynecologists; HTN, hypertension; NICE, Na/onal Ins/tute for Health and Clinical
Excellence
Vest AR, Cho LS. Cardiol Clin 30 (2012) 407–423
An8hypertensive Drugs in Pregnancy (1)

Methyldopa : firstline agent historically because it is
associated with stable uteroplacental blood flow &
fetal hemodynamic
Calcium channel blocker (Long-ac/ng formula/on):
firstline agent. Nifedipine, Dil/azem, Verapamil is
safe.
Beta-blockers : safety issue is controversial due to
reports of premature labor, fetal growth retarda/on,
neonatal apnea, bradycardia & hypoglycemia.
Should probably be avoided before third semester.
An8hypertensive Drugs in Pregnancy (2)
Diure8cs : the use of diure/c remains controversial.
Not contraindicated in pregnancy except in sekng in
uretoplacental perfusion is already reduced (i.e.
preeclampsia and/or fetal growth retarda/on
Drug ac8ng on Renin-Angiotensin System :
contraindicated, even in women are planning to
become pregnant (increased risk of malforma/ons,
fetal growth retarda/on, oligohydramnions, neonatal
renal failure, neonatal death)
Labetalol (alpha & beta-blockers) : firstline agent
according of many experts. Not available in Indonesia
Preven/on of preeclampsia
•  Low dose aspirin : use advised in women at
high risk
•  Fish oil supplementa/on : not recomended
•  Calcium supplementa/on : use advised in low
calcium intake popula6on
•  Vitamin C and E : not remcomended
•  Other an/-oxidant : not recomended

Brown CM, Garovic VD. Drugs. 2004;74:283-296


Patient Considered for Low-dose Apsirin

•  One of the following high-risk features:


ü History of preeclampsia
ü Multifetal gestation
ü Chronic hypertension
ü Diabetes (type I or type II)
ü Renal disease
ü Autoimmune disease

•  Multiple moderate risk factors:


ü Nulliparity
ü Obesity
ü Family history of preeclampsia
ü African American race
ü Age ≥35
ü Low socioeconomic status
ü Characteristics of previous pregnancy

Naderi S et al. Curr Atheroscler Rep. 2017;19:15-21.


Schausberger CE et al. Geburtsh Frauenheilk 2013;73: 7–52

Pregnancy Hypertension 2012;2:350–357


The risk of future disease following hypertensive pregnancy/
preeclampsia

Green A et al. Royal Coll. Obstet. Gynaecol. 2012;14:99-105.


Mechanism Common to Hypertensive
Disorders of Pregnancy and CVD

1.  Endothelial dysfunc/on


2.  Metabolic abnormality
3.  Oxida/ve stress
4.  Inflammatory response
5.  Hypercoagulability

Garovic VD, Hayman SR. Nat Clin. Pract. Nephrol. 2007;3(11):613-622


Summary
•  Hypertensive disorder represent major causes of pregnancy-relared morbidity and
mortality worldwide.

•  Hypertension in pregnancy consist of chronic (preexis/ng) hypertension,


gestasional hypertension, preeclampsia-Eclampsia and super imposed
preeclampsia in chronic hypertension.

•  The op/mal /ming and choice of therapy for hypertensive pregnancy disorders
involves carefully weighing the risk-versus-benefit ra/o for each individual pa/ent,
with an overall goal of improving maternal and fetal outcomes.

•  Methyldopa and calcium channel blocker can be used as a firstline drugs. Diure/cs
and betablockers can be used as a secondline drugs by taking into account risk-
benefit ra/o. Drugs ac/ng on renin-angiotensin system are contraindicated in
pregnancy.

•  Increasing evidence indicates that hypertension in pregnancy is an


underrecognized risk factor for cardiovascular disease



Thank you

You might also like